Ozempic probed by EU drug regulator
Weight management medications under investigation after a small number of reports of suicidal risks were referred to the watchdog
The European Union’s drug regulator has launched a probe into Novo Nordisk A/S’s weight-loss medications after a small number of reports of suicidal risks were referred to the watchdog.
The European Medicines Agency (EMA) is looking at adverse events noted by the Icelandic Medicines Agency. According to a statement from the EMA on Monday, these include two cases of suicidal thoughts linked to the drugs Saxenda and Ozempic.
Suicidal behaviour is not currently listed as ...